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Background: Progressive neurodegeneration in Alzheimer’s disease (AD) induces cognitive deterioration, and there
is controversy regarding the optimal treatment strategy in early AD. Stimulation therapy, including physical exercise
and cholinesterase inhibitors are both reported to postpone cognitive deterioration in separate studies. We aimed
to study the effect of stimulation therapy and the additional effect of donepezil on cognitive function in early AD.
Method: Design: A two-by-two factorial trial comprising stimulation therapy for one year compared to standard
care to which a randomized double-blinded placebo controlled trial with donepezil was added.
Setting: Nine rural municipalities in Northern Norway.
Participants: 187 participants 65 years and older with a recent diagnosis of mild or moderate AD were included in
the study of which 146 completed a one-year follow-up. INTERVENTIONS: In five municipalities the participants
received stimulation therapy whereas participants in four received standard care. All participants were randomised
double-blindly to donepezil or placebo and tested with three different cognitive tests four times during the one-
year study period.
Main outcome: Changes in MMSE sum score.
Secondary outcome: Changes in ADAS-Cog and Clock Drawing Test.
Results: MMSE scores remained unchanged amongst AD participants receiving stimulation therapy and those
receiving standard care. The results were consistent for ADAS-Cog and Clock Drawing Test. No time trend
differences were found during one-year follow-up between groups receiving stimulation therapy versus standard
care or between donepezil versus placebo.
Conclusion: In rural AD patients non-pharmacological and pharmacological therapy did not improve outcome
compared with standard care but all groups retained cognitive function during one year follow-up. Other studies
are needed to confirm these results.
Trial registration: ClinicalTrials.gov (Identifier: NCT00443014). EudraCT database (no 2004-002613-37).
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Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder causing cognitive impairment in millions
of elderly worldwide. Clinical practice today includes
symptomatic treatment with stimulation therapy and/or
pharmaceutical intervention with cholinesterase inhibi-
tors (ChEI) due to lack of causal treatment [1,2].
Non-pharmaceutical interventions on AD such as ex-
ercise training, occupational therapies and cognitive
stimulation have been examined in studies of various de-
sign, size and duration. Until recently such interventions
have not been tested in large-scale studies [3]. A
Cochrane review (2003) described limited effects of cog-
nitive stimulation therapy alone[4], but a meta-analysis
including 30 trials studying the effect of exercise training
in AD patients showed a significant effect on cognitive
and functional performance as compared to the control
group [5]. Graff and colleagues showed that occupational
therapy improved cognitive function significantly and
reduced the burden on caregivers [6]. Despite controver-
sies, ChEIs have been promoted during the last fifteen
years as symptomatic treatment of mild to moderate
AD. Several meta-analyses have reported a modest effect
of ChEI on cognition [7-9]. A head to head comparison
of the effect of ChEI versus stimulation therapy has to
our knowledge not been performed [3] although the
combined effect of donepezil and stimulation therapyTable 1 Baseline cognitive, neuropsychological and ADL func
Groups n MMSE± SD* ADAS-co
Municipality
Stimulation 103 22.9 ± 4.6 18.9 ±
Standard care 77 23.5 ± 4.3 17.1 ±
p-value 0.34 0.22
Drug
Donepezil 90 23.2 ± 4.2 18.6 ±
Placebo 90 23.1 ± 4.8 17.9 ±
p-value 0.83 0.55
Combination
Donepezil 53 22.9 ± 4.5 19.2 ±
+ stimulation
Placebo
+ Standard care 40 23.3 ± 4.9 17.2 ±
p-value 0.64 0.24
Head to head
Stimulation therapy 50 22.9 ± 4.7 18.5 ±
Donepezil 37 23.7 ± 3.7 17.6 ±
p-value 0.36 0.62
*Mean values ± Standard deviation. **CDT =Clock Drawing Test scale 0–4 (4 best fu
{ NPI =Neuropsychiatric Inventory, Scale 0–144 (144 worst case).compared to control groups is examined in a few studies
[10-12].
The main purpose of this study was to examine the ef-
fect of stimulation therapy on cognitive function in
community dwellers with mild to moderate AD in
Northern Norway. A secondary aim was to examine




The present study has a double design; - an open inter-
vention with stimulation therapy to which a randomised
double blinded and placebo-controlled clinical trial
(RCT) with donepezil is added, constituting a two-by-
two factorial design.
Participants
General practitioners (GPs) recruited 87 and population-
based screening 100 participants to the study, all with a re-
cent diagnosis of AD at inclusion. 45 of these 187 partici-
pants (24%) were nursing home residents served by the
primary health care in the participating municipalities and
142 lived in their own homes. 146 participants accom-
plished a one-year follow-up. At baseline no significant dif-
ferences between subgroups were found with respect to
age, gender, cognitive function, neuropsychiatric symptoms,tion according to follow-up groups
g± SD* CDT**± SD* BI}±SD* NPI{±SD*
8.7 2.85 ± 1.2 6.08 ± 96 18.6 ± 2.6
7.0 2.84 ± 1.2 8.48 ± 105 18.6 ± 3.2
0.96 0.12 0.995
7.7 2.86 ± 1.1 7.48 ± 114 18.9 ± 2.1
8.4 2.84 ± 1.2 6.70 ± 89 18.4 ± 3.4
0.95 0.61 0.29
8.7 2.92 ± 1.1 6.29 ± 113 18.7 ± 2.3
8.0 2.93 ± 1.2 7.76 ± 104 18.1 ± 4.0
0.998 0.53 0.45
8.7 2.78 ± 1.3 5.85 ± 74 18.6 ± 2.8
5.8 2.76 ± 1.3 9.29 ± 108 19.1 ± 1.8
0.93 0.09 0.31
nction) }BI = Barthel Index, scale 0–20 (20 best function).
Figure 1 Flowchart of dropouts during follow-up.
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morbidities or education level (Table 1 and Table 2).
The recruitment methods and demographic charac-
teristics are described in detail in a previous paper [13].
Inclusion criteria were individuals aged 65–100 years
with a recent diagnosis of AD and Mini-Mental-State
-Examination (MMSE) [14] sum score at least 10 points.
A standard MMSE protocol translated into Norwegian
was used and the protocol was not changed during the
study period. At entry 43 participants tested between 10
and 20 MMSE points, 92 participants tested between 21
and 25 points and 52 participants tested 26 MMSE
points or more.
Exclusion criteria were dementia other than AD, previ-
ous use of donepezil, behavioural disturbances making
co-operation and cognitive testing impossible, inability
to understand the purpose of the study, any expressed
reluctance to participate, or relatives or caregivers disap-
proving participation. The study period lasted for
39 months of which 27 involved recruitment. All to-
gether 41 participants (22%) dropped out, seven prior to
the first test and 34 between the first and the fourth
(Figure 1).
The study was community based and run on munici-
pality level. Nine rural municipalities in Northern Nor-
way with 70000 inhabitants were engaged. The age
group ≥65 years in these communities constituted 11807
individuals. The municipalities were divided into two
groups. Participants from five municipalities receivedTable 2 Baseline demographic characteristics according to follow-up groups
Groups Age± SD* Gender Education Living
Female ≤ 7 yerars Couple Comorbidity Drug use
n (%) n (%) n (%) ± SD* ± SD*
Municipality
Stimulation 81.6 ± 6.7 59(57) 88(85) 48(46) 1.82 ± 1.7 4.89 ± 3.3
Standard care 4.89 ± 3.3 54(65) 65(79) 37(45) 1.65 ± 1.1 5.40 ± 3.9
p-value 0.12 0.25 0.34 0.83 0.45 0.34
Drug
Donepezil 80.80 ± 6.8 62(67) 82(89) 39(42) 1.90 ± 1.7 5.10 ± 3.3
Placebo 80.85 ± 7.3 50(54) 70(75) 46(49) 1.59 ± 1.2 5.16 ± 3.8
p-value 0.96 0.07 0.014 0.30 0.15 0.90
Combination
Donepezil + stimulation 81.32 ± 7.0 31(60) 47(90) 28(54) 2.02 ± 2.0 4.92 ± 2.8
Placebo + Standard care 79.81 ± 8.1 22(54) 29(71) 19(46) 1.51 ± 1.1 5.41 ± 3.9
p-value 0.34 0.57 0.015 0.47 0.14 0.48
Head to head
Stimulation therapy 81.89 ± 8.3 27(53) 40(78) 24(47) 1.61 ± 1.4 4.88 ± 3.7
Donepezil 80.17 ± 6.4 28(74) 32(86) 15(39) 1.76 ± 1.3 5.26 ± 4.0
p-value 0.21 0.046 0.33 0.45 0.61 0.65
*Mean values ± standard deviation.
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remaining four received standard care. The municipal-
ities were selected to the study and allocated to stimula-
tion therapy or standard care according to criteria such
as number of inhabitants, age distribution and ethnical
homogeneity. Professional competence level and a pri-
mary health care organized in accordance with the prin-
ciples of good clinical practice in each participating
municipality were required. Choosing maximum dis-
tance and pursuing the least contact possible between
municipalities offering stimulation therapy or standard
care intended to minimize the risk of dilution. These se-
lection criteria were difficult to apply by random alloca-
tion, and each municipality was assigned to the
intervention or control municipality group based on
study staff consensus.
Randomisation and masking
The Clinical Research Centre at the University Hospital
in Tromsø allocated all participants to donepezil or pla-
cebo (drug groups) in a randomised manner, in blocks of
4 to 6, by (Figure 2). The treatment assignments were
blinded to all study personnel and participants.
Diagnosing Alzheimer’s disease
A standardised testing program according to national
guidelines was used. A semi-structured interview of the
participants concentrating on the onset and the course
of memory impairment, visuo-spatial disturbances,
speech difficulties, executive dysfunctions, and problems
with activities of daily living was performed. A family
member or a caregiver completed or extended the med-
ical history by adressing the Informant Questionnaire-
Cognitive Decline in the Elderly (IQ-CODE) [15] which
also assess social consequences of the cognitive impair-
ment. Cognitive function was tested with MMSE andFigure 2 Flowchart of the study design and sample size divided on suClock Drawing Test (CDT) [16]. Depressive symptoms
were assessed with a semi-structured questionnaire in
addition to Montgomery and Aasberg Depression Rating
Scale (MADRS) [17] testing AD participants with a
MMSE sum score exceeding 21 points. A neurological
examination, blood tests and cerebral computed tomog-
raphy (CT) were performed. The diagnostic procedures
for participants recruited by screening were similar to
those used in general practice.
GPs and geriatric specialists diagnosed dementia and
Alzheimer’s disease according to the ICD-10 criteria [18]
and the Statistical Manual of Mental Disorders fourth
edition (DSM-IV-TR). Diagnostic discrepancies were dis-
cussed with a geriatric colleague both advised by Na-
tional Institute of Neurological and Communicative
Disorders and Stroke-Alzheimer Disease and Related
Disorders (NINCDS-ADRDA) criteria [19] for probable
AD and solved by consensus. A third specialist (MV)
was consulted if disagreement continued.
Outcome measures
The primary outcome was changes in MMSE sum score.
In order to compare with other studies the cognitive
tests were supplemented with Alzheimer’s Disease As-
sessment Scale, Cognitive (ADAS-Cog) [20]. A change
in ADAS-Cog and CDT were secondary outcomes. Basic
activities of daily living were assessed with Barthel Index
(BI) [21]. NeuroPsychiatric Inventory (NPI) [22] was
used to identify psychiatric symptoms.
During one-year follow-up MMSE, CDT and ADAS-
Cog were performed at baseline and at 4, 8 and 12 months,
and all other tests at baseline and at 12 months. Two test
technicians performed all testing after supervision and
training at The Department of Geriatrics, University Hos-
pital in Northern Norway. To improve intra and inter-
rater reliability they observed and evaluated each other bybgroups.
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NPI prior to the study onset.
Intervention
Stimulation therapy
A program of stimulation therapy including physical ac-
tivities, cognitive, sensory and social stimulation was
developed and adjusted to each participant taking cog-
nitive and physical function, educational level and pro-
fessional background into consideration. The program
included systematically performed and intensified daily
activities like walking, domestic work, regular reading
of books and papers, training in fitness rooms, dancing,
crossword puzzles, listening to music, and regular par-
ticipation in the social life of the community. A few
more sophisticated activities such as reminiscence
groups, Sudoku, aroma therapy and sensory garden
were added, between which the participants could move
freely. This stimulation therapy was carried out for a
minimum of 30 minutes 5 days a week for one year
(maximum 250 sessions a year) in close co-operation
with the participant and his/her family or trained health
providers. Each session of stimulation therapy was
described in a log which was submitted to the study site
weekly. These were then compared to the pre-plan indi-
vidual stimulation program and assessed consecutively,
approved or rejected by the study staff. In nursing
homes the employee conducted the stimulation therapy
while community nurses or other caregivers (family
members or even neighbors) guided by the nurses were
responsible for the stimulation therapy of community
dwellers not regularly receiving community health care.
The stimulation program was monitored and adjusted
according to functional abilities and interests of the
participants during the period of intervention. Nursing
home residents and community dwellers received the
same stimulation program with an exception for the in-
dividual adjustment. Participants living in municipal-
ities allocated to standard care did not receive any
organized stimulation.
Drug
Having received the randomization codes the pharmacy
at the hospital in Bodø distributed the drugs to the pa-
tient or the caregiver according to a prescription from
the family physician. All participants were prescribed
donepezil or placebo once daily. Passing four weeks the
dosage was increased from 5 to 10 mg. Adverse events
were recorded consecutively.
Ethics and approvals
The present study was approved by the national authorities
including The Regional Committee for Medical Research
Ethics in Northern Norway, The Privacy Ombudsman forResearch, The Directory of Health and Social Welfare and
The Norwegian Medicine Agency with registration in the
EudraCT database (no 2004-002613-37). Each participant
gave a written informed consent co-signed by a spouse, a
close relative or a guardian. The national authorities listed
above approved the consent formula and the study was
registered as an International Standard Randomized
Controlled Trial within ClinicalTrials.gov (Identifier:
NCT00443014). In October 2008 The Norwegian Medicine
Agency conducted an inspection according to the principles
of Good Clinical Practice in a randomized clinical trial. All
remarks from this assessment, including monitoring rou-
tines were closed and approved.
All the publications from this study comply with
The CONSORT statements 2010 and the updated
Uniform Requirements for Manuscripts Submitted to
Biomedical Journals.
Statistics
Statistical analyses were carried out using SPSS version
15.0 and 18 (SPSS Inc. Chicago, US). Differences in demo-
graphic characteristics between municipality and medicine
groups were assessed by independent sample t-tests or
Chi-square. Repeated measures analyses assessed differ-
ences in time-trends between groups of participants com-
pleting one-year follow-up. Linear mixed models were
used to assess time-trends in cognitive function over four
time points and to assess differences in time-trends be-
tween groups of participants with and without baseline
cognitive function as covariate. Including an unstructured
covariance matrix to the model controlled for possible
dependences between repeated observations. In the muni-
cipality groups, time trend differences in cognitive func-
tion were assessed between the stimulation group and
controls, and differences in the medicine groups were
assessed between donepezil treatment group and placebo.
Finally, the subgroup treated by stimulation therapy and
donepezil was compared to the subgroup receiving usual
care and placebo. Model assumptions were assessed by
means of residual analyses. The statistical analyses were
performed according to intention to treat, per protocol
and subgroup analyses in order to estimate homogeneity
and consistency of the data. In sensitivity analyses we
included municipality as random effect in the linear mixed
models in order to control for possible clustering of data
within the municipalities.
Results
No significant time trend differences in cognitive per-
formance were observed between participants receiving
stimulation therapy or standard care during one year,
assessed by MMSE (primary outcome), CDT and ADAS-
Cog (secondary outcome). The cognitive test performances
remained unchanged during the study period, and addition
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the results (Table 3 and Table 4). Repeated measures ana-
lyses were consistent with the linear mixed model analyses
(Data not shown).
When comparing stimulation therapy and donepezil
head to head, time-trend analysis showed non-significant
changes for CDT and ADAS-Cog, whereas the MMSE test
showed borderline significance (p= 0.042) (Table 5). A
subgroup analysis comparing the extremes, the combined
effect of stimulation therapy and donepezil versus stand-
ard care and placebo, did not reveal any significant time-
trend differences in cognitive performance (Table 6). In-
cluding municipality as a random factor did not change
the main result of the study (data not shown).
Baseline demographic characteristics were well balanced
between compared groups with respect to, cognitive
performance, activities of daily living (ADL), neuropsychi-
atric symptoms (NPI) (Table 1), age, gender, social living,
drug consumption and co-morbidities (Table 2). The edu-
cational level was significantly lower in the donepezil
group compared to placebo (Table 2). Of 187 study parti-
cipants, 146 completed one year follow-up, and 41 with-
drew due to disease progression (n= 8), co-morbidityTable 3 Mean cognitive function in the municipality and drug
analyses
Groups
Baseline, n = 180 4 months, n = 158 8
MMSE±
Municipality
Stimulation (n = 103) 22.9 ± 4.6 22.1 ± 5.0 2
Standard care (n = 77) 23.5 ± 4.3 23.8 ± 4. 2
Drug
Donepezil (n = 90) 23.2 ± 4.2 23.3 ± 4.5 2
Placebo n= 90 23.1 ± 4.1 22.9 ± 4.8 2
Clock Drawing
Municipality
Stimulation 2.9 ± 1.2 2.9 ± 1.1 2
Standard care 2.8 ± 1.2 3.0 ± 1.2 3
Drug
Donepezil 2.9 ± 1.2 2.8 ± 1.2 2
Placebo 2.8 ± 1.1 3.0 ± 1.1 3
ADAS-cog
Municipality
Stimulation 18.9 ± 8.7 18.5 ± 8.4 1
Standard care 17.4 ± 7.0 16.1 ± 6.9 1
Drug
Donepezil 18.6 ± 7.6 17.7 ± 7.8 1
Placebo 17.9 ± 8.4 17.1 ± 7.9 1
*n varies due to dropouts during follow-up. ** Standard deviation. p-value1 = Equal
adjusted for baseline cognitive function.(n= 8), death (n= 7), or unknown reason (n= 18) (Fig-
ure 1). The dropouts were equally distributed between
subgroups. At entry the dropouts were older (82.5 ± 7.1
versus 80.4 ± 6.9 years), and more cognitively impaired
(MMSE 21.17 ± 4.1 versus 23.48 ± 3.7) compared to those
completing the study period.
22 participants (25%) dropped out from the donepezil
group due to adverse reactions compared to 8 (10%) in
the placebo group, p = 0.008 (data not shown). 17 parti-
cipants in the donepezil group reported gastrointestinal
reactions, especially anorexia, diarrhoea and nausea
compared to 6 in the placebo group. Participants using
donepezil reported depression, dizziness, nightmare and
headache whereas these symptoms were uncommon in
the placebo group. In two cases the adverse reactions
were temporarily and the medication could be resumed.
In the other cases the symptoms remained and the drug
treatment had to be interrupted.
Discussion
In this one-year trial, there were no significant changes
in cognitive performance between AD participants re-
ceiving stimulation therapy or standard care. To ourgroups by follow-up time point. Intention to treat
Moments of follow-up
months n = 153 12 months,* n = 146 p-value1 p-value2
SD**
2.9 ± 4.5 22.6 ± 5.2 0.15 0.017
4.4 ± 4.0 23.9 ± 4.3
3.8 ± 4.3 23.0 ± 4.9 0.31 0.21
3.4 ± 4.3 23.3 ± 4.8
Test ± SD**
.8 ± 1.1 3.0 ± 1.1 0.21 0.071
.1 ± 1.1 3.1 ± 1.1
.8 ± 1.2 3.0 ± 1.0 0.56 0.26
.0 ± 1.0 3.1 ± 1.1
± SD**
7.0 ± 9.1 16.8 ± 8.5 0.23 0.11
5.7 ± 8.2 15.9 ± 8.0
6.3 ± 8.8 16.3 ± 8.4 0.59 0.24
6.5 ± 8.6 16.4 ± 8.2
time trends between groups. p-value2 = Equal time trend between groups
Table 4 Estimated change in cognitive function by follow-up time point and according to drug groups and
municipality groups*
Estimated change (95% CI) versus baseline at p-values
Groups 4 months 8 months, 12 months P 1 P 2
MMSE
Drug groups
Placebo −0.402 (−0.988, 0.185) −0.015 (−0.584, 0.553) −0.335 (−1.046, 0.375) 0.208 0.284
Donepezil 0.145 (−0.440, 0.730) 0.411 (−0.166, 0.988) −0.470 (−1.181, 0.241)
Municipality groups
Standard care 0.198 (−0.429, 0.826) 0.790 ( 0.190, 1.389) 0.156 (−0.588, 0.901) 0.017 0.508
Stimulation −0.380 (−0.933, 0.172) −0.272 (−0.807, 0.262) −0.841 (−1.510, -0.172)
Clock Drawing Test
Drug groups
Placebo 0.103 (−0.081, 0.288) 0.124 (−0.082, 0.330) 0.134 (−0.079, 0.347) 0.264 0.570
Donepezil −0.016 (−0.200, 0.169) −0.101 (−0.309, 0.107) 0.031 (−0.183, 0.245)
Municipality groups
Standard care 0.120 (−0.076, 0.317) 0.210 (−0.008, 0.428) 0.234 ( 0.011, 0.456) 0.071 0.257
Stimulation −0.017 (−0.191, 0.158) −0.144 (−0.339, 0.050) −0.038 (−0.242, 0.165)
ADAS-cog
Drug groups
Placebo −0.383 (−1.412, 0.646) −1.126 (−2.201, -0.051) −0.492 (−1.635, 0.650) 0.235 0.886
Donepezil −1.027 (−2.053, -0.001) −1.948 (−3.033, -0.862) −1.510 (−2.661, -0.359)
Municipality groups
Standard care −1.515 (−2.597, -0.433) −1.736 (−2.889, -0.582) −1.619 (−2.830, -0.407) 0.108 0.242
Stimulation −0.069 (−1.030, 0.893) −1.380 (−2.407, -0.352) −0.493 (−1.590, 0.603)
* Linear mixed models adjusted for baseline cognitive score.
P1, p-value for overall equality of change between the groups.
P2, p-value for test of interaction between group and time, i.e. test for constant differences between groups over time.
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and the results were consistent for three different cogni-
tive tests as assessed at quarterly sessions during the
study period. Among the participants receiving standard
care, we expected an annual decline of 2–3 MMSETable 5 Mean cognitive function by follow-up time point and
donepezil versus stimulation therapy
Groups Time points
Baseline n = 87 4 months n= 76 8 m
MMSE± S
Stimulation therapy 22.9 ± 4.5 22.2 ± 5.1
Donepezil 23.7 ± 3.7 23.8 ± 3.8
Clock Drawing T
Stimulation therapy 2.8 ± 1.3 2.9 ± 1.2
Donepezil 2.8 ± 1.3 2.7 ± 1.3
ADAS-cog ±
Stimulation therapy 18.5 ± 8.7 17.9 ± 8.6
Donepezil 17.6 ± 5.8 15.8 ± 6.9
n varies due to missing values ** Standard deviation. p-value1 = Equal time trends b
baseline cognitive function.points, or an increase of 5–12 ADAS-Cog points, which
is the natural course of AD [23,24].
Our results are in agreement with others [25,26] who
reported small changes in mean MMSE score in controls
receiving standard care. This is in contrast with Requenaaccording to a head to head comparison between
p-value1 p-value2
onths n = 74 12 months* n= 69
D**
23.0 ± 4.0 22.7 ± 4.8 0.040 0.0016
25.1 ± 3.0 23.6 ± 3.8
est ± SD**
2.8 ± 1.0 2.9 ± 1.1 0.940 0.713
2.8 ± 1.2 2.9 ± 1.1
SD**
16.7 ± 8.8 17.6 ± 8.6 0.225 0.060
15.1 ± 7.9 16.7 ± 8.1
etween groups. p-value2 = Equal time trend between groups adjusted for
Table 6 Mean cognitive function by follow-up time point and according to donepezil added to stimulation therapy
versus placebo added to standard care
Groups Time points
Baseline n = 87 4 months n =76 8 months n= 74 12 months* n = 69 p-value1 p-value2
MMSE± SD**
Donepezil + stimulation therapy 22.9 ± 4.5 22.9 ± 4.5 22.9 ± 4.9 22.5 ± 5.5 0.443 0.449
Placebo+ standard care 23.3 ± 4.9 23.8 ± 4.2 23.6 ± 4.6 24.1 ± 4.7
Clock Drawing Test ± SD**
Donepezil + stimulation therapy 2.9 ± 1.1 2.9 ± 1.1 2.8 ± 1.2 3.1 ± 1.0 0.064 0.035
Placebo+ standard care 2.9 ± 1.2 3.2 ± 1.0 3.3 ± 1.0 3.3 ± 1.1
ADAS-cog± SD**
Donepezil + stimulation therapy 19.3 ± 8.7 19.2 ± 8.2 17.2 ± 9.5 16.1 ± 8.7 0.554 0.458
Placebo+ standard care 17.2 ± 8.0 16.3 ± 7.1 16.3 ± 8.5 15.1 ± 7.9
* n varies due to missing values ** Standard deviation. p-value1 = Equal time trends between groups. p-value2 = Equal time trend between groups adjusted for
baseline cognitive function.
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MMSE score from 19.4 (SD 4.9) to 13.1 (SD 5.9) after
one year without intervention, but an increase in mean
MMSE score from 19.4 (SD 8.2) to 21.9 (SD 7.9) after
one year for AD subjects receiving stimulation therapy.
However, these studies are limited by short follow up
[25], retrospective design, poorly defined controls [26],
small sample size and an open design [10].
In our study, there were no differences in cognitive per-
formance between the groups given donepezil or placebo,
irrespective of stimulation therapy or standard care. Chap-
man et al [12] and Matsuda et al [11] reported non-
significant changes in mean MMSE score in the combined
treatment group given donepezil and stimulation therapy
after one year (−1.3 and +0.3 respectively), but a significant
reduction in cognitive performance was observed in the
donepezil only group (−2.9 and −2.0 respectively). Requena
et al reported improved mean MMSE score (+1.5 points)
after one year and a minimal reduction after two years in
the combined treatment group (−1.3 points), whereas AD
participants receiving donepezil without specific stimula-
tion and AD participants in the control group had signifi-
cantly lower MMSE score (−3.4 and −6.3, respectively).
Our results partially support these studies [10-12] as the
effect of stimulation on cognitive performance, with or
without donepezil, did not deteriorate after one year. How-
ever, unlike Requena et al, our participants receiving done-
pezil or placebo added to standard care retained cognitive
performance after one year. The differences could be due
to smaller sample size and greater variation in cognitive
function among participants in the Requena et al study
compared to the present study. Differences in baseline
cognitive function between mild and moderate AD may
also give different cognitive deterioration slopes.In a recent systematic review, Olazarán et al [27] has
evaluated best effect of nonpharmacological therapies.
Evidence of potential grade A treatment recommenda-
tion was reported for the effect of multicomponent
intervention in delaying institutionalisation and grade
B treatment recommendation for improvement in cog-
nition and of activity of daily living. The intervention
program of the present study is in accordance with
these recommendations.
Several events and mechanisms may explain the
similar cognitive performances between participants
receiving stimulation therapy and standard care. In our
study all groups were engaged in some treatment regi-
men also the standard care group that received pla-
cebo. We suggest that even this group was exposed to
more than standard care throughout the study period
because of overly enthusiastic co-workers including
test technicians who became involved in activities that
exceeded their predefined roles. Frequent monitoring
and follow-ups do increase the attention given to the
patients by family members, caregivers and study staff.
This may act as stimulation in itself and generate an
expectancy of a beneficial outcome [28]. We know
from the experiences of industrial companies that pro-
duction may increase no matter what changes are
introduced to the workers or working conditions, “the
Hawthorne effect” [29]. The Hawthorn effect has to
our knowledge only been addressed in one single AD
study [30]. This effect is not sufficiently described in
clinical AD trials [31,32], and it may contribute to con-
trols performing better than expected.
Beside the above-mentioned mechanisms, our study
results may have been affected by a national AD cam-
paign launched at the same time. That campaign
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tion. This could have contributed to a diffusion of the
therapeutic procedures across municipality borders
and diluted the differences between stimulation ther-
apy and standard care.
Strengths and weaknesses
Our study is population-based with few exclusion cri-
teria. This is different from several other studies which
recruited AD individuals from hospitals, memory clinics
or nursing homes using restrictive inclusion and wide
exclusion criteria that could influence study samples and
results. Our study population is ethnically and socially
homogenous, and the baseline characteristics did not
differ between defined strata. The two-by-two factorial
design in our study enables a head to head comparison
between stimulation therapy and drug treatment
Participants remained in their own environment dur-
ing the entire study period. None of the participants
used memantin or other ChEI. Although 23% of the par-
ticipants used anticholinergic drugs for co-morbidities
[33], inappropriate drugs were equally distributed be-
tween groups and could hardly explain the results.Our
participants received structured stimulation therapy on a
daily basis and had few dropouts (22%), and the drop-
outs were equally distributed among subgroups. A pos-
sible weakness is that lower MMSE score among
dropouts could have influenced mean cognitive deterior-
ation during follow-up. However, repeated measure ana-
lyses confirmed the main result of the study.
Another possible weakness is that despite randomisa-
tion, participants in the donepezil group had a lower
educational level compared to the placebo group. Less
education is associated with an increased risk of AD [2]
but it is questionable whether this risk factor has an in-
fluence on the cognitive trajectory in AD in any way.
The non-randomized allocation of the participating mu-
nicipalities to stimulation therapy or standard care could
be considered a weakness. However, a sensitivity analysis
done to control for possible clustering of data within the
municipalities did not change the results. The ability of
the applied tests to detect a change in cognitive per-
formance is questioned in early stage AD [18]. However,
a stratified analysis of a subgroup presenting a MMSE
score less than 21 points at entry (n = 43) showed no dif-
ferences, and the results were consistent for all three
cognitive tests (data not shown). It is therefore unlikely
that a MMSE learning effect has occurred.
Furthermore, the stratified samples in the two-by-two
factorial analysis that we did could be prone to type II
errors due to relatively small sample sizes - especially the
subgroup analyses of participants with MMSE< 21. How-
ever, the differences between all groups were consistent
for all three tests. Another consequence of the two-by-twofactorial design was that no subgroup was left without any
intervention. Even the standard care group received either
placebo or donepezil. This could have increased the ex-
pectancy of a favourable outcome in the control groups
and diluted the results [28].
Conclusion
Participants with recently diagnosed AD receiving
stimulation therapy retained cognitive function during
the one-year follow-up as did also AD participants re-
ceiving standard care. Donepezil therapy had no add-
itional effect on cognition. Our results need to be
confirmed in future studies.
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